Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
http://www.nature.com/articles/bmt2010212.pdf
Reference15 articles.
1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ . Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116: 546–554.
2. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber Jr MJ . Tumor lysis syndrome. Semin Thromb Hemost 2007; 33: 397–407.
3. Wu XW, Lee CC, Muzny DM, Caskey CT . Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989; 86: 9412–9416.
4. Leach M, Parsons RM, Reilly JT, Winfield DA . Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol 1998; 20: 169–172.
5. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998–3003.
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effectiveness of a Single Fixed Dose of 3 mg Rasburicase for the Prevention and Management of Hyperuricemia in Tumor Lysis Syndrome in Adults With Cancer;Cureus;2024-09-04
2. A retrospective review of rasburicase utilization in pediatric and adult patients across a large health system;Journal of Oncology Pharmacy Practice;2024-05-25
3. Emergencies;Tata Memorial Centre Textbook of Oncology;2024
4. Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices;Journal of Oncology Pharmacy Practice;2023-08-10
5. A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome;Leukemia & Lymphoma;2023-02-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3